AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24475198 — intervention group
Group type: EXPERIMENTAL
Intervention: Active case detection method (children monitored actively, visited twice weekly, tympanic temperature measured, malaria rapid diagnostic test performed if fever present)
Number of subjects: 0
Study 24475198 — intervention group
Group type: COMPARATOR
Intervention: Passive case detection method (children monitored passively, parents/caregivers asked to bring children to clinic if unwell)
Number of subjects: 0
Study 21837394 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal lorazepam (2 mg)
Number of subjects: 12
Study 21837394 — intervention group
Group type: COMPARATOR
Intervention: Buccal lorazepam (2 mg)
Number of subjects: 12
Study 20646129 — intervention group
Group type: EXPERIMENTAL
Intervention: Let's Face It! (LFI!) computer-based intervention, 20 hours of face training
Number of subjects: 42
Study 20646129 — intervention group
Group type: COMPARATOR
Intervention: Waitlist group (control)
Number of subjects: 42
Study 17208382 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA (titrated up to 150mg)
Number of subjects: 40
Study 17208382 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 15650833 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based daily exercise therapy (20-min exercise program once per day for 8 weeks)
Number of subjects: 0
Study 15650833 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based daily exercise therapy
Number of subjects: 0
Study 15650833 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 0
Study 12815801 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antihistamines and topical steroids
Number of subjects: 34
Study 9672123 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.15 mg/kg)
Number of subjects: 21
Study 9672123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 9672123 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 21
Study 7728916 — intervention group
Group type: EXPERIMENTAL
Intervention: AVS plus intravenous immunoglobulin (IVIG)
Number of subjects: 0
Study 7728916 — intervention group
Group type: COMPARATOR
Intervention: Standard AVS therapy
Number of subjects: 0
Study 2547917 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol
Number of subjects: 4
Study 2547917 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 4
Study 2547917 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 4
Study 2547917 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 4
Study 2547917 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 4
Study 1200268 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (30 mg/kg)
Number of subjects: 50
Study 1200268 — intervention group
Group type: COMPARATOR
Intervention: No corticosteroids (Control)
Number of subjects: 50
Study 31221218 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid ablation
Number of subjects: 40
Study 31221218 — intervention group
Group type: COMPARATOR
Intervention: (Repeated) catheter ablation
Number of subjects: 40
Study 27845857 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned health education (3 educational sessions at 2-week intervals)
Number of subjects: 247
Study 25742794 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine with magnesium sulfate USP 50%
Number of subjects: 100
Study 25742794 — intervention group
Group type: COMPARATOR
Intervention: Placebo (distilled water)
Number of subjects: 100
Study 23467275 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF (5 μg/kg per day, six doses) plus standard therapy
Number of subjects: 55
Study 23467275 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy only
Number of subjects: 55
Study 21510270 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO2)
Number of subjects: 232
Study 19061203 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment doses (specific doses not mentioned)
Number of subjects: 0
Study 19061203 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study 16813265 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI
Number of subjects: 90
Study 16813265 — intervention group
Group type: COMPARATOR
Intervention: CSII
Number of subjects: 90
Study 16813265 — intervention group
Group type: COMPARATOR
Intervention: IVII
Number of subjects: 90
Study 12737682 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide from PassCal Clickhaler (1,000 microg)
Number of subjects: 0
Study 12737682 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide from Lactose Clickhaler (1,000 microg)
Number of subjects: 0
Study 12737682 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide from Pulmicort Turbuhaler (1,000 microg)
Number of subjects: 0
Study 12737682 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide from Pulmicort Turbuhaler (2,000 microg)
Number of subjects: 0
Study 12737682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10931049 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized leg ulcer clinics in East Gloucestershire
Number of subjects: 200
Study 10931049 — intervention group
Group type: COMPARATOR
Intervention: West Gloucestershire control
Number of subjects: 200
Study 8966826 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiopeptin (750 micrograms/day)
Number of subjects: 112
Study 8966826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 1410142 — intervention group
Group type: EXPERIMENTAL
Intervention: m-chlorophenylpiperazine (MCPP) 0.25 mg/kg
Number of subjects: 17
Study 1410142 — intervention group
Group type: EXPERIMENTAL
Intervention: m-chlorophenylpiperazine (MCPP) 0.5 mg/kg
Number of subjects: 17
Study 1410142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 1410142 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender comparison
Number of subjects: 17
Study 2933926 — intervention group
Group type: COMPARATOR
Intervention: iohexol
Number of subjects: 19
Study 2933926 — intervention group
Group type: EXPERIMENTAL
Intervention: meglumine metrizoate
Number of subjects: 19
Study 3318896 — intervention group
Group type: COMPARATOR
Intervention: Nalbuphine 10 mg ml‐1 (group N)
Number of subjects: 55
Study 3318896 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 0.15 mg ml‐1 (group B)
Number of subjects: 55
Study 29241652 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 μg roflumilast
Number of subjects: 100
Study 29241652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 28667397 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) treatment
Number of subjects: 16
Study 28667397 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PRP)
Number of subjects: 16
Study 25960304 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin 5 mg/d
Number of subjects: 5466
Study 25960304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5466
Study 23805859 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 25 mg/day
Number of subjects: 144
Study 23805859 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg/day
Number of subjects: 144
Study 23805859 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 21164498 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan/HCTZ
Number of subjects: 207
Study 21164498 — intervention group
Group type: COMPARATOR
Intervention: Olmesartan/Azelnidipine
Number of subjects: 207
Study 19027483 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib (250 mg per day orally)
Number of subjects: 1466
Study 19027483 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (75 mg/m2 intravenously every 3 weeks)
Number of subjects: 1466
Study 19027483 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib in patients with high EGFR-gene-copy number
Number of subjects: 1466
Study 19027483 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel in patients with high EGFR-gene-copy number
Number of subjects: 1466
Study 19027483 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 1466
Study 19027483 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 1466
Study 16585435 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (1.5-6.0 mg/day)
Number of subjects: 444
Study 16585435 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (7.5-30 mg/day)
Number of subjects: 444
Study 16585435 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (200-800 mg/day)
Number of subjects: 444
Study 16585435 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone (40-160 mg/day)
Number of subjects: 444
Study 16585435 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 444
Study 16585435 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 444
Study 16585435 — intervention group
Group type: COMPARATOR
Intervention: Quetiapine and Ziprasidone
Number of subjects: 444
Study 12631592 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy with docetaxel plus doxorubicin or paclitaxel
Number of subjects: 15
Study 11216491 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg isoflavones
Number of subjects: 40
Study 11216491 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg isoflavones
Number of subjects: 40
Study 11216491 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg and 40 mg isoflavones
Number of subjects: 40
Study 11216491 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone tablets
Number of subjects: 40
Study 8828069 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefozopran (CZOP) at 10 mg/kg
Number of subjects: 17
Study 8828069 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefozopran (CZOP) at 20 mg/kg
Number of subjects: 17
Study 8828069 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefozopran (CZOP) at 40 mg/kg
Number of subjects: 17
Study 1617765 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 686
Study 1617765 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 686
Study 3882526 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (0.5 mg/h intravenously, preceded by a three day oral loading at 10 mg tid)
Number of subjects: 6
Study 3882526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 3882526 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 6
Study 31227470 — intervention group
Group type: EXPERIMENTAL
Intervention: Supporting Cushions (SC)
Number of subjects: 22
Study 31227470 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic Techniques (HT)
Number of subjects: 22
Study 29729825 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive nutrition intervention (individualized nutrition and exercise counselling; 12 dietitian visits; 3 exercise physiologist visits over 12 months)
Number of subjects: 37
Study 29729825 — intervention group
Group type: COMPARATOR
Intervention: Standard nutrition care (guideline based; 4 dietitian visits)
Number of subjects: 37
Study 29729825 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort (both groups)
Number of subjects: 37
Study 27977721 — intervention group
Group type: EXPERIMENTAL
Intervention: Miconazole nitrate mucoadhesive tablets (10 mg) once daily for 14 days
Number of subjects: 343
Study 27977721 — intervention group
Group type: COMPARATOR
Intervention: Itraconazole capsules (100 mg QD) for 14 days
Number of subjects: 343
Study 24413548 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS-guided depth of anesthesia
Number of subjects: 310
Study 24413548 — intervention group
Group type: COMPARATOR
Intervention: End‐tidal anesthetic concentration-guided depth of anesthesia
Number of subjects: 310
Study 21859212 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted lifestyle intervention (¡Viva Bien!)
Number of subjects: 280
Study 21859212 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 280
Study 20151087 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive + predominant breastfeeding
Number of subjects: 330
Study 20151087 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal anemia
Number of subjects: 330
Study 20151087 — intervention group
Group type: EXPERIMENTAL
Intervention: Type of flooring at home, type of delivery, birthweight
Number of subjects: 330
Study 18545188 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training for 14 weeks
Number of subjects: 11
Study 18545188 — intervention group
Group type: EXPERIMENTAL
Intervention: Detraining for 4 weeks
Number of subjects: 11
Study 15805999 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen-specific immunotherapy (SIT)
Number of subjects: 35
Study 15805999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 15805999 — intervention group
Group type: COMPARATOR
Intervention: Out-seasonal ratings
Number of subjects: 35
Study 15805999 — intervention group
Group type: EXPERIMENTAL
Intervention: In-seasonal reports
Number of subjects: 35
Study 12143204 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous allopurinol
Number of subjects: 16
Study 12143204 — intervention group
Group type: COMPARATOR
Intervention: No allopurinol
Number of subjects: 16
Study 9804023 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin + clavulanic acid (Spektramox)
Number of subjects: 386
Study 9804023 — intervention group
Group type: COMPARATOR
Intervention: Penicillin-V (Primcillin)
Number of subjects: 386
Study 7666706 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard gamble method
Number of subjects: 229
Study 7666706 — intervention group
Group type: EXPERIMENTAL
Intervention: Rating scale method
Number of subjects: 229
Study 7666706 — intervention group
Group type: EXPERIMENTAL
Intervention: Chained gambles
Number of subjects: 229
Study 7666706 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe hypothetical state
Number of subjects: 229
Study 2514810 — intervention group
Group type: EXPERIMENTAL
Intervention: NeoCalme
Number of subjects: 26
Study 2514810 — intervention group
Group type: COMPARATOR
Intervention: Valium
Number of subjects: 26
Study 711799 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction drainage
Number of subjects: 100
Study 711799 — intervention group
Group type: COMPARATOR
Intervention: No suction drainage (Control)
Number of subjects: 100
Study 30717830 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy (VRET)
Number of subjects: 30
Study 30717830 — intervention group
Group type: COMPARATOR
Intervention: Informational pamphlet (IP)
Number of subjects: 30
Study 29502375 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical Jiaji electroacupuncture
Number of subjects: 39
Study 29502375 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide combined with chlorpromazine
Number of subjects: 39
Study 29502375 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical Jiaji electroacupuncture (for patients who resisted control treatment)
Number of subjects: 39
Study 26901657 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted cognitive behavioral therapy
Number of subjects: 100
Study 23945999 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg hydrocortisone
Number of subjects: 32
Study 23945999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 22352813 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping-skills training
Number of subjects: 137
Study 22352813 — intervention group
Group type: COMPARATOR
Intervention: Standard asthma education (attention control)
Number of subjects: 137
Study 20850039 — intervention group
Group type: EXPERIMENTAL
Intervention: Pectoralis minor soft tissue mobilization (STM) and self‐stretching
Number of subjects: 28
Study 20850039 — intervention group
Group type: COMPARATOR
Intervention: Placebo touch and pectoralis major self‐stretching
Number of subjects: 28
Study 17178181 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 400 mg q.i.d. on days 1 and 2
Number of subjects: 46
Study 16078288 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultant general surgeons
Number of subjects: 2000
Study 16078288 — intervention group
Group type: COMPARATOR
Intervention: Consultant physicians
Number of subjects: 2000
Study 16078288 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 2000
Study 12072603 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (H2RA)
Number of subjects: 285
Study 12072603 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 285
Study 9478092 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous production of interleukin-1 beta by monocytes
Number of subjects: 25
Study 9478092 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS stimulated production of interleukin-1 beta by monocytes
Number of subjects: 25
Study 9478092 — intervention group
Group type: COMPARATOR
Intervention: Control group of 23 healthy males
Number of subjects: 25
Study 7885295 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitization to storage mites among cattle farmers
Number of subjects: 0
Study 7885295 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (not specified)
Number of subjects: 0
Study 7885295 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with mite species in cattle barns
Number of subjects: 0
Study 7885295 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-sensitization to Dermatophagoides
Number of subjects: 0
Study 3129969 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 120
Study 3129969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 29859274 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone based text messaging lifestyle intervention (n=271)
Number of subjects: 394
Study 29859274 — intervention group
Group type: COMPARATOR
Intervention: Standard care advice (n=266)
Number of subjects: 394
Study 28821576 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention strategy (theoretical and practical counseling once yearly for 3 years)
Number of subjects: 300
Study 28821576 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention strategy
Number of subjects: 300
Study 28821576 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 300
Study 26278651 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial pacing
Number of subjects: 46
Study 26278651 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventricular pacing
Number of subjects: 46
Study 26278651 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual ECG interpretation for atrial pacing
Number of subjects: 46
Study 26278651 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual ECG interpretation for ventricular pacing
Number of subjects: 46
Study 23207237 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish (FV) application every 6 months
Number of subjects: 543
Study 23207237 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish (FV) application
Number of subjects: 543
Study 20948557 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counselling with probiotics (Lactobacillus rhamnosus GG and Bifidobacterium lactis)
Number of subjects: 256
Study 20948557 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counselling with placebo
Number of subjects: 256
Study 20948557 — intervention group
Group type: COMPARATOR
Intervention: Control/placebo group
Number of subjects: 256
Study 20948557 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 256
Study 18440920 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg qd
Number of subjects: 71
Study 18440920 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg
Number of subjects: 71
Study 16956340 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal pulse oximetry (FPO) added to conventional cardiotocographic (CTG) monitoring
Number of subjects: 0
Study 16956340 — intervention group
Group type: COMPARATOR
Intervention: Conventional cardiotocographic (CTG) monitoring alone
Number of subjects: 0
Study 12697884 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy + RT
Number of subjects: 179
Study 12697884 — intervention group
Group type: COMPARATOR
Intervention: RT alone
Number of subjects: 179
Study 10728951 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (30 mg/kg)
Number of subjects: 72
Study 10728951 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 8957727 — intervention group
Group type: EXPERIMENTAL
Intervention: HCl
Number of subjects: 47
Study 8957727 — intervention group
Group type: EXPERIMENTAL
Intervention: HCl/Pepsin
Number of subjects: 47
Study 8957727 — intervention group
Group type: COMPARATOR
Intervention: NaCl
Number of subjects: 47
Study 8957727 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 47
Study 8957727 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with RE
Number of subjects: 47
Study 8141126 — intervention group
Group type: EXPERIMENTAL
Intervention: ABO-identical platelet transfusions
Number of subjects: 0
Study 8141126 — intervention group
Group type: COMPARATOR
Intervention: ABO-unmatched platelet transfusions
Number of subjects: 0
Study 3138681 — intervention group
Group type: EXPERIMENTAL
Intervention: misoprostol 400 micrograms twice daily for 28 days
Number of subjects: 12
Study 3138681 — intervention group
Group type: EXPERIMENTAL
Intervention: propranolol 80 mg twice daily for four weeks with misoprostol 400 micrograms twice daily during the second and third weeks
Number of subjects: 12
Study 31831193 — intervention group
Group type: EXPERIMENTAL
Intervention: No-touch saphenous vein (NT SV) graft
Number of subjects: 108
Study 31831193 — intervention group
Group type: COMPARATOR
Intervention: Radial artery (RA) graft
Number of subjects: 108
Study 31831193 — intervention group
Group type: COMPARATOR
Intervention: Left internal thoracic artery (LITA)
Number of subjects: 108
Study 31274266 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel ultrasound-guided bracket-assisted technique for axillary vein catheter placement
Number of subjects: 35
Study 29848400 — intervention group
Group type: EXPERIMENTAL
Intervention: REACH intervention
Number of subjects: 32000